Novo launches online news channel for hemophilia patients; Sanofi's MS pill slows brain atrophy in Phase III;

> Novo Nordisk ($NVO) has launched an online news channel as part of its new website for hemophilia patients, RareBleedingDisorders.com. More

> Sanofi's ($SNY) multiple sclerosis pill, Aubagio, slowed brain atrophy in a Phase III trial. Release

> The U.S. Department of Health and Human Services (HHS) is considering ideas to control drug prices, including contracting with drugmakers to pay based on performance. More (sub. req.)

> Formycon and Bioeq have launched a Phase III trial of their biosimilar of Roche's ($RHHBY) Lucentis. Report

And Finally... A guerrilla advertising campaign in Australia is encouraging gay men to have unprotected sex to promote Gilead's ($GILD) Truvada, which reduces the risk of contracting HIV. More

Suggested Articles

Novartis is taking its MBC campaign to Instagram with a newly launched video series as part of the five-year “Make Your Dialogue Count” effort.

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.